Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns
Rising Prevalence and Increasing Disease Awareness to Drive Significant Growth
The prevalence of asthma in the assessed countries is a prominent contributor towards the market size. In the Asia-Pacific region, the prevalence of asthma is high in the aging population and in children (Song et al., 2014). As the aging population in this region increases, it will lead to greater asthma prevalence. Moreover, the severity of asthma is commonly higher in the aging population, meaning elderly patients will require more medications to control their symptoms, which will also drive the market (Kopnina, 2012). In addition to the aging population, other factors such as increases in air pollution, dust, and pollen levels also contribute to the increase in asthma prevalence (Nadkar et al., 2015). Air pollution leads to both the occurrence of the disease and its exacerbation in children, and there is growing evidence of asthma symptoms in children who live near roadways in high traffic zones (Kopnina, 2012).
Awareness of the disease condition In the Asia-Pacific region is increasing among the public, resulting in an increase in diagnosis and treatment rates. As more number of patients receive drug treatment, this again will drive the market.
There are six costly biologics that are set to enter the Asia-Pacific asthma therapeutics market. These consist of mepolizumab, reslizumab, lebrikizumab, dupilumab, tralokinumab, and benralizumab, which are being developed by GlaxoSmithKline (GSK), Teva, Chugai/Roche, Sanofi/Regeneron, AstraZeneca, and AstraZeneca, respectively.
New Market Entrants Will Boost Market Growth During Forecast Period
These new products will help to diminish the impact of increased generic competition over the forecast period. Currently, there is no approved therapy for the treatment of severe eosinophilic asthma, which creates a significant unmet need in this sub-set patient population. However, among the six biologics in late-stage development, four biologics – mepolizumab, reslizumab, dupilumab, and benralizumab – are being developed for the treatment of severe eosinophilic asthma, and if approved they will address the unmet need.
There are six promising biologics in late-stage development, and four of them are expected to address the current unmet need that exists for the treatment of severe eosinophilic asthma. However, all of these biologics are likely to be priced highly, and hence affordability will be a strong barrier that will restrict the overall market growth. In India, among the six late-stage biologics, only reslizumab is under development, despite the fact that India has the highest asthma prevalence population across the five Asia-Pacific markets. Similarly, in China, only mepolizumab is under development, despite China having the second highest asthma prevalence population after India. In addition, the only approved biologic – Xolair (omalizumab) – is yet to be approved in China, and although it has been available in India since before 2009, its market uptake there is negligible. These findings clearly indicate that there is significant drug affordability concern in India and China.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook